Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease.

@article{Giordano2017ComparisonOB,
  title={Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease.},
  author={A. Giordano and P. Ferraro and N. Corcione and S. Messina and G. Maresca and E. Coscioni and Raffaella Avellino and G. Giordano and M. Peruzzi and A. Marullo and G. Napolitano and M. Romano and G. Biondi-Zoccai},
  journal={Current vascular pharmacology},
  year={2017},
  volume={15 3},
  pages={
          257-264
        }
}
BACKGROUND Drug-eluting stents (DES) are now considered the most promising device to treat peripheral artery disease (PAD) and minimize restenosis. There is uncertainty however on the best antirestenotic drug for such devices. In particular, biolimus (i.e. umirolimus) and everolimus are two of the most promising agents, given the extensive data in support of their coronary safety and efficacy, but their comparative effectiveness for peripheral interventions is not established. METHODS… Expand